title: Novel anticoagulants for the prevention and treatment of venous thromboembolism.
abstract: Unfractionated heparin, low molecular weight heparin and vitamin K antagonists are anticoagulants currently used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. Considerable limitations of these agents, such as a narrow therapeutic window, a variable dose response or lack of oral bioavailability, created the need for new anticoagulants. Numerous new compounds with different mechanisms of action have been developed and some have been already approved for clinical use. Quite recently, fondaparinux, an indirect anti-factor Xa inhibitor, has been licensed in Europe and in the US for prevention of VTE in patients undergoing hip or knee replacement surgery. In addition, lepirudin, a recombinant hirudin derivative, and the heparinoid danaparoid, have been approved in Austria for treatment of heparin-induced thrombocytopenia. Recombinant nematode anticoagulant protein c2, the orally available thrombin inhibitor ximelagatran and ART-123, a recombinant soluble thrombomodulin, are in advanced stages of clinical development. This article reviews mechanisms and sites of action, and the current state of preclinical and clinical research of these and various other agents with respect to the prevention and treatment of venous thromboembolism).
authors.affiliation: Division of Hematology and Hemostaseology, Department of Internal Medicine I, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. ansgar.weltermann@akh-wien.ac.at
authors.forename: Ansgar
authors.initials: A
authors.lastname: Weltermann
authors.forename: Paul A
authors.initials: PA
authors.lastname: Kyrle
authors.forename: Sabine
authors.initials: S
authors.lastname: Eichinger
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001384:Azetidines; D001596:Benzylamines; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors; D015507:Drugs, Investigational / Q000627:therapeutic use; D000077425:Fondaparinux; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012106:Research; D013917:Thrombin / Q000037:antagonists & inhibitors; D020246:Venous Thrombosis / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D001779:Blood Coagulation Factors; D015507:Drugs, Investigational; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D014812:Vitamin K; C109573:melagatran; D006493:Heparin; D013917:Thrombin; D000077425:Fondaparinux; D005998:Glycine